Danish Construction Stock News

Ever wondered if Novo Nordisk is a hidden gem or an overhyped story? If you want the real scoop on what the stock is worth, you’re in the right place. The stock has been anything but dull lately. It is up 9.6% in the last week, barely changed over the past month, but still down over 50% year-to-date and in the last 12 months, despite gaining more than 60% over five years. Recent news has seen Novo Nordisk in the headlines, from major regulatory developments to ongoing buzz around its...

Danske Bank (CPSE:DANSKE) shares have shown steady momentum over the past month, gaining 2% as investors digest a stretch of modest revenue and net income growth. The stock’s performance stands out, especially in light of broader volatility in European banking. See our latest analysis for Danske Bank. Danske Bank’s share price has climbed 45.3% year-to-date, suggesting growing optimism around its fundamentals and outlook. The one-year total shareholder return of nearly 61% puts recent price...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

The DonkeyRepublic Holding A/S ( CPH:DONKEY ) share price has fared very poorly over the last month, falling by a...

Coloplast A/S ( CPH:COLO B ) is about to trade ex-dividend in the next 4 days. The ex-dividend date is commonly two...

The Shape Robotics A/S ( CPH:SHAPE ) share price has fared very poorly over the last month, falling by a substantial...

RTX (CPSE:RTX) just released its full-year 2025 earnings, reporting fourth-quarter revenue of 146.7 million DKK and basic EPS of 0.55 DKK. Looking back, the company has seen revenue fluctuate, with figures ranging from 104.0 million DKK to 165.5 million DKK over the last four quarters, and basic EPS swinging from a loss of -0.90 DKK in Q1 to a high of 0.99 DKK in Q2. With EPS returning to positive territory and net income rising in recent quarters, investors are paying close attention to...

FirstFarms (CPSE:FFARMS) just posted its Q3 2025 financials, reporting total revenue of 367.992 million DKK and basic EPS of 0.53 DKK. Net income excluding extraordinary items was -6.366 million DKK. Over the past few quarters, revenue has ranged from 89.82 million DKK to 126.923 million DKK, with EPS fluctuating between -1.35 DKK and 1.43 DKK. This reflects ongoing volatility rather than consistent growth. With investor attention focused on weak margins, these results highlight the challenge...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

If you have ever wondered whether A.P. Møller Mærsk is really a bargain or just cruising on its reputation, you are not alone. Let us break down what might make this shipping giant undervalued or overpriced right now. The stock has moved 3.6% higher in the last week, but is still down 7.1% over the past month, with a year-to-date return of 1.6% and a solid 19.0% gain over the past year. These movements give investors a lot to consider in terms of growth or changing risk signals. Recently,...

Gabriel Holding A/S ( CPH:GABR ) recently posted some strong earnings, and the market responded positively. We did some...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Key Insights Institutions' substantial holdings in H+H International implies that they have significant influence over...

In November 2025, Novo Nordisk announced that its Evoke and Evoke+ phase 3 trials found oral semaglutide did not significantly slow progression in early-stage Alzheimer's disease, prompting the company to discontinue a planned extension of the studies. This outcome marks a setback in the company's efforts to expand GLP-1-based medicines beyond diabetes and obesity into neurology, highlighting the challenges of diversifying its drug pipeline while facing increased competition in core...

Rockwool (CPSE:ROCK B) has just released its Q3 2025 results, reporting revenue of €963 million and basic EPS of €0.6, with net income (excluding extra items) at €122 million. Looking back, the company has seen revenues move from €957 million in Q3 2024 through varying quarters to €963 million this quarter. EPS has ranged between €0.54 and €0.7 per share across recent results. Margins settled somewhat from last year's levels, reflecting steady but less dynamic profitability as investors weigh...

Curious if Genmab is a bargain right now? Let’s dive into what might make this innovative biotech stock an appealing buy, or a candidate for caution. After an impressive 32.5% rally year-to-date and a 34.3% jump over the last 12 months, Genmab’s stock has been firmly in the spotlight, suggesting renewed investor optimism. Several partnership announcements and drug development milestones have fueled Genmab’s price momentum recently, with news flow focused on promising pipeline progress and...

Vestjysk Bank (CPSE:VJBA) has just posted its Q3 2025 results, recording revenue of 508.9 million DKK and net income (excluding extra items) of 196.5 million DKK. Looking back, the company has seen revenue hover in the 477 to 574 million DKK range across the last five quarters, while net income (excluding extra items) fluctuated between 173.9 million DKK and 257.9 million DKK. Investors will note that margins have compressed over the period, setting the stage for a closer look at longer-term...

TCM Group (CPSE:TCM) has just reported Q3 2025 results, posting revenue of 288.9 million DKK and basic EPS of 0.93 DKK, with net income at 9.6 million DKK for the quarter. Over the past twelve months, revenue has climbed from 1,189.4 million DKK to 1,247.5 million DKK, up 8.2% year-over-year. Net income rose from 29.8 million DKK to 66.9 million DKK, reflecting a 65.9% increase. With profit margins expanding and earnings momentum building, the latest numbers set the stage for investors to...

With a price-to-earnings (or "P/E") ratio of 17.5x Demant A/S ( CPH:DEMANT ) may be sending bearish signals at the...

Key Insights The projected fair value for PARKEN Sport & Entertainment is kr.175 based on Dividend Discount Model With...

Vestas Wind Systems A/S ( CPH:VWS ) shares have had a really impressive month, gaining 25% after a shaky period...

Key Insights Ambu's Annual General Meeting to take place on 3rd of December Salary of kr.8.01m is part of CEO Britt...

Key Insights Per Aarsleff Holding's significant retail investors ownership suggests that the key decisions are...

Novo Nordisk (CPSE:NOVO B) shares have edged slightly higher, continuing a pattern of modest moves over the past week. Investors appear to be digesting recent financial data while assessing the stock's performance in a changing market environment. See our latest analysis for Novo Nordisk. While Novo Nordisk’s share price has bounced in the last trading session, the stock is still working to rebuild momentum after a challenging stretch. Over the past year, shareholders have seen a total return...